CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM

RTOG 3508/AbbVie M13-813/INTELLANCE-1 was a phase 3 trial of depatuximab-mafodotin (depatux-m, formerly ABT-414) that accrued 639 patients with EGFR-amplified newly diagnosed GBM. At the pre-specified interim OS analysis, the futility criteria were met and there was no survival benefit from adding d...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Wefel, Jeffrey S, Won, Minhee, Lassman, Andrew, Stern, Yaakov, Wang, Tony, Aldape, Kenneth, Armstrong, Terri, Vogelbaum, Michael, Sulman, Erik, Moazami, Golnaz, Macsai, Marian, Gilbert, Mark, Bain, Earle, Blot, Vincent, Gan, Hui, Preusser, Matthias, Ansell, Peter, Samanta, Suvajit, Kundu, Madan, Seidel, Clemens, de Vos, Filip, Hsu, Sigmund, Cardona, Andres, Lombardi, Giuseppe, Bentsion, Dmitry, Peterson, Richard, Gedye, Craig, Lebrun-Frenay, Christine, Wick, Antje, Pugh, Stephanie, Curran, Walter, Mehta, Minesh
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Clinical Trials: Non-Immunologic
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650869/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.217
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia